QUE Oncology is developing novel therapies to treat cancer and alleviate cancer-related symptoms.
While great progress has been made in cancer treatment, many forms of cancer still lack effective treatments. Additionally, many existing treatments come with side effects that are intolerable for some patients.
QUE Oncology is pursuing treatments to fill these gaps. It has a growing portfolio of drug-based assets to treat cancer or negative effects associated with cancer treatment. QUE’s leading drug candidate, Q-122, may offer a non-hormonal way to treat hot flashes in women with breast cancer who are receiving anti-estrogen therapy.
The company was founded by researchers from Emory University and the University of Queensland’s research commercialization company, UniQuest.
Company website: Que Oncology
Back to companies
Location: Australia, Victoria, Melbourne
Employees: 11-50
Founded date: 2013
Investors 3
| Date | Name | Website |
| - | Georgia Re... | gra.org |
| - | Brandon Ca... | brandoncap... |
| - | Stoic VC | stoicvc.co... |
Mentions in press and media 5
| Date | Title | Description | Source |
| 11.11.2022 | QUE Oncology’s non-hormonal therapy reduces hot flushes and ... | QUE Oncology announces the results of its Phase II trial of Q-122, a novel non-hormonal oral therapy... | brandoncap... |
| 23.10.2019 | QUE Oncology recruiting Sydney breast cancer patients experi... | Melbourne biotechnology company QUE Oncology has announced that the Royal North Shore Hospital is ac... | brandoncap... |
| 01.08.2019 | QUE Oncology launches Phase II trials in New Zealand | Australian biotechnology company QUE Oncology today announces the launch of its Phase II trials whic... | brandoncap... |
| 02.04.2019 | QUE Oncology launches Phase II trials in the United States | Clinical stage biotechnology company QUE Oncology today announces the launch of its Phase II trials ... | brandoncap... |
| 02.10.2018 | QUE Oncology launches Phase II trials | Clinical stage biotechnology company QUE Oncology today announces the launch of its Phase II trials ... | brandoncap... |